fluorouracil has been researched along with Carcinoma, Adenosquamous in 46 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The data from two phase III trials for oesophageal cancer were used." | 2.80 | Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. ( Ando, N; Fukuda, H; Hayashi, K; Igaki, H; Kataoka, K; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Ozawa, S, 2015) |
| "Gemcitabine was given intravenously at a dose of 1000 mg/m(2) over 30 min on days 1, 8 and 15, repeated every 4 weeks." | 2.75 | Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. ( Boku, N; Fukuda, H; Fukutomi, A; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Nakamura, K; Ohkawa, S; Okusaka, T, 2010) |
| "Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year." | 2.73 | A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K, 2007) |
| "Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy." | 2.73 | Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K, 2007) |
| "Four hundred three women with cervical cancer were randomly assigned to receive either EFRT or CTRT." | 2.71 | Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. ( Cooper, J; Eifel, PJ; Gershenson, D; Grigsby, PW; Levenback, C; Morris, M; Mutch, DG; Rotman, M; Winter, K, 2004) |
| "Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years." | 2.71 | Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. ( Ansari, R; Fineberg, N; Fox, E; Govindan, R; Hanna, N; Helft, P; Kesler, K; Mantravadi, P; McLeod, H; Stoner, C, 2004) |
| "All patients had biopsy-proven invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix." | 2.69 | Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. ( Bundy, BN; Clarke-Pearson, DL; Fowler, WC; Hannigan, EV; Liao, SY; Malfetano, JH; Sause, W; Whitney, CW, 1999) |
| "In the UK, the standard of care for esophageal cancer has generally combined surgery with neoadjuvant chemotherapy, with definitive chemoradiotherapy (dCRT) being reserved for certain subgroups." | 2.52 | Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. ( Cook, N; Gilligan, D; Hategan, M; Hindmarsh, A; Prewett, S; Qian, W, 2015) |
| "Of 216 stage IIIB cervical cancer patients, 114 of them had no LTI and 72 had LTI." | 1.46 | Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion. ( Katanyoo, K, 2017) |
| "Pancreatic cancer is known for its typically late presentation and poor survival rates, with overall 5-year survival of less than 5%." | 1.42 | Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report. ( Brais, RJ; Chatzizacharias, NA; Corrie, P; Davies, S; Elias, A; Harper, SJF; Huguet, E; Jah, A; Jamieson, NV; Praseedom, RK; Xanthis, A, 2015) |
| "To study the efficacy of low-dose-rate californium-252 ((252)Cf) neutron intracavitary afterloading radiotherapy (RT) combined with external pelvic RT for treatment of cervical cancer." | 1.38 | Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer. ( Lin, S; Liu, JR; Pan, SD; Xu, HD; Yue, JH; Zhang, M, 2012) |
| "Even after curative resection of pancreatic cancer, there is a high probability of systemic recurrence." | 1.37 | Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. ( Baba, H; Beppu, T; Hirota, M; Ikeda, O; Kanemitsu, K; Oya, N; Takamori, H; Tanaka, H; Yamashita, Y, 2011) |
| "Esophageal adenosquamous carcinoma is a rare esophageal disease and prone to be misdiagnosed as esophageal squamous cell carcinoma." | 1.35 | [Clinical analysis of 22 cases of esophageal adenosquamous carcinoma]. ( Fu, JH; Lin, P; Long, H; Ma, GW; Rong, TH; Su, XD; Zhang, DK; Zhang, LJ, 2009) |
| "101 patients with cervical cancer FIGO IB1-IVB underwent chemoradiation after transperitoneal laparoscopic staging." | 1.34 | Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. ( Bischoff, A; Budach, V; Füller, J; Köhler, C; Marnitz, S; Roth, C; Schneider, A; Wendt, T, 2007) |
| "Multiple lymph node metastasis were detected by CT scan." | 1.29 | [A case of advanced esophageal cancer showing good partial response by combination therapy of low dose 5-FU and low dose CDDP]. ( Aisawa, T; Akagi, T; Fukushi, M; Ishiguro, Y; Kimura, S; Kudoh, I; Osanai, S; Sakata, Y; Suzuki, H; Takemori, H; Yoshiike, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (26.09) | 18.2507 |
| 2000's | 21 (45.65) | 29.6817 |
| 2010's | 12 (26.09) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Auvray Kuentz, M | 1 |
| Hautefeuille, V | 1 |
| de Mestier, L | 1 |
| Coutzac, C | 1 |
| Lecomte, T | 1 |
| Nardon, V | 1 |
| Artru, P | 1 |
| Turpin, A | 1 |
| Drouillard, A | 1 |
| Malka, D | 1 |
| Tran-Minh, ML | 1 |
| Trouilloud, I | 1 |
| Lièvre, A | 1 |
| Williet, N | 1 |
| Pernot, S | 1 |
| Touchefeu, Y | 1 |
| Taieb, J | 1 |
| Hammel, P | 1 |
| Zaanan, A | 1 |
| Bascoul-Mollevi, C | 1 |
| Gourgou, S | 1 |
| Galais, MP | 1 |
| Raoul, JL | 1 |
| Bouché, O | 1 |
| Douillard, JY | 1 |
| Adenis, A | 1 |
| Etienne, PL | 1 |
| Juzyna, B | 1 |
| Bedenne, L | 1 |
| Conroy, T | 1 |
| Katanyoo, K | 1 |
| Hategan, M | 1 |
| Cook, N | 1 |
| Prewett, S | 1 |
| Hindmarsh, A | 1 |
| Qian, W | 1 |
| Gilligan, D | 1 |
| Rose, PG | 1 |
| Java, JJ | 1 |
| Whitney, CW | 2 |
| Stehman, FB | 1 |
| Lanciano, R | 1 |
| Thomas, GM | 1 |
| Elias, A | 1 |
| Chatzizacharias, NA | 1 |
| Xanthis, A | 1 |
| Corrie, P | 1 |
| Davies, S | 1 |
| Brais, RJ | 1 |
| Jamieson, NV | 1 |
| Praseedom, RK | 1 |
| Huguet, E | 1 |
| Harper, SJF | 1 |
| Jah, A | 1 |
| Kataoka, K | 1 |
| Nakamura, K | 2 |
| Mizusawa, J | 1 |
| Fukuda, H | 2 |
| Igaki, H | 1 |
| Ozawa, S | 1 |
| Hayashi, K | 1 |
| Kato, K | 2 |
| Kitagawa, Y | 1 |
| Ando, N | 1 |
| Nakajima, TE | 1 |
| Ura, T | 1 |
| Ito, Y | 1 |
| Minashi, K | 1 |
| Nihei, K | 1 |
| Hironaka, S | 1 |
| Boku, N | 2 |
| Kagami, Y | 1 |
| Muro, K | 1 |
| Koopman, M | 1 |
| Kortman, GA | 1 |
| Mekenkamp, L | 1 |
| Ligtenberg, MJ | 1 |
| Hoogerbrugge, N | 1 |
| Antonini, NF | 1 |
| Punt, CJ | 1 |
| van Krieken, JH | 1 |
| Gold, DG | 1 |
| Miller, RC | 1 |
| Haddock, MG | 2 |
| Gunderson, LL | 2 |
| Quevedo, F | 1 |
| Donohue, JH | 1 |
| Bhatia, S | 1 |
| Nagorney, DM | 1 |
| Zhang, DK | 1 |
| Su, XD | 1 |
| Lin, P | 1 |
| Long, H | 1 |
| Fu, JH | 1 |
| Zhang, LJ | 1 |
| Ma, GW | 1 |
| Rong, TH | 1 |
| Ishii, H | 2 |
| Furuse, J | 1 |
| Okusaka, T | 1 |
| Ikeda, M | 1 |
| Ohkawa, S | 1 |
| Fukutomi, A | 1 |
| Hamamoto, Y | 1 |
| Takamori, H | 1 |
| Kanemitsu, K | 1 |
| Hirota, M | 1 |
| Ikeda, O | 1 |
| Tanaka, H | 1 |
| Beppu, T | 1 |
| Yamashita, Y | 1 |
| Oya, N | 1 |
| Baba, H | 1 |
| Lee, HN | 1 |
| Lee, KH | 1 |
| Lee, DW | 1 |
| Lee, YS | 1 |
| Park, EK | 1 |
| Park, JS | 1 |
| McCaffrey, R | 1 |
| Bahtiyar, M | 1 |
| Kohorn, EI | 1 |
| Chambers, JT | 1 |
| Schwartz, PE | 1 |
| Chambers, SK | 1 |
| Ohkuma, M | 1 |
| Haraguchi, N | 1 |
| Mimori, K | 1 |
| Tanaka, F | 1 |
| Kim, HM | 1 |
| Shimomura, M | 1 |
| Hirose, H | 1 |
| Yanaga, K | 1 |
| Mori, M | 1 |
| Zhang, M | 1 |
| Xu, HD | 1 |
| Pan, SD | 1 |
| Lin, S | 1 |
| Yue, JH | 1 |
| Liu, JR | 1 |
| Suzuki, E | 1 |
| Hirai, R | 1 |
| Ota, T | 1 |
| Shimizu, N | 1 |
| Graf, R | 1 |
| Wust, P | 1 |
| Hildebrandt, B | 1 |
| Gögler, H | 1 |
| Ullrich, R | 1 |
| Herrmann, R | 1 |
| Riess, H | 1 |
| Felix, R | 1 |
| Goldberg, M | 1 |
| Farma, J | 1 |
| Lampert, C | 1 |
| Colarusso, P | 1 |
| Coia, L | 1 |
| Frucht, H | 1 |
| Goosenberg, E | 1 |
| Beard, M | 1 |
| Weiner, LM | 1 |
| Lim, JT | 1 |
| Truong, PT | 1 |
| Berthelet, E | 1 |
| Pai, H | 1 |
| Joe, H | 1 |
| Wai, E | 1 |
| Larsson, S | 1 |
| Kader, HA | 1 |
| Weinerman, B | 1 |
| Wilson, K | 1 |
| Olivotto, IA | 1 |
| Eifel, PJ | 5 |
| Winter, K | 3 |
| Morris, M | 1 |
| Levenback, C | 1 |
| Grigsby, PW | 3 |
| Cooper, J | 1 |
| Rotman, M | 1 |
| Gershenson, D | 1 |
| Mutch, DG | 3 |
| Govindan, R | 1 |
| McLeod, H | 1 |
| Mantravadi, P | 1 |
| Fineberg, N | 1 |
| Helft, P | 1 |
| Kesler, K | 1 |
| Hanna, N | 1 |
| Stoner, C | 1 |
| Ansari, R | 1 |
| Fox, E | 1 |
| Uchikado, Y | 1 |
| Natsugoe, S | 1 |
| Okumura, H | 1 |
| Matsumoto, M | 1 |
| Setoyama, T | 1 |
| Takigawa, J | 1 |
| Haraguchi, Y | 1 |
| Ishigami, S | 1 |
| Aikou, T | 1 |
| Gaffney, DK | 2 |
| Dicker, AP | 2 |
| Miller, B | 2 |
| Ryu, J | 2 |
| Avizonis, V | 2 |
| Fromm, M | 2 |
| Greven, K | 2 |
| Small, W | 1 |
| Marnitz, S | 1 |
| Köhler, C | 1 |
| Roth, C | 1 |
| Füller, J | 1 |
| Bischoff, A | 1 |
| Wendt, T | 1 |
| Schneider, A | 1 |
| Budach, V | 1 |
| Torres, MA | 1 |
| Jhingran, A | 1 |
| Thames, HD | 1 |
| Levenback, CF | 1 |
| Bodurka, DC | 1 |
| Ramondetta, LM | 1 |
| Kobayashi, Y | 1 |
| Wada, Y | 1 |
| Ohara, T | 1 |
| Okuda, Y | 1 |
| Suzuki, N | 1 |
| Hasegawa, K | 1 |
| Kiguchi, K | 1 |
| Ishizuka, B | 1 |
| Shibagaki, K | 1 |
| Fujita, K | 1 |
| Nakayama, S | 1 |
| Takenaka, M | 1 |
| Fukuba, N | 1 |
| Matsui, S | 1 |
| Ozaka, M | 1 |
| Yoshinaga, H | 1 |
| Masuzawa, A | 1 |
| Watanabe, A | 1 |
| Fujiwara, H | 1 |
| Sugawara, A | 1 |
| Fujita, T | 1 |
| Mukai, H | 1 |
| Kinoshita, Y | 1 |
| Cai, HY | 1 |
| Akagi, T | 1 |
| Sakata, Y | 1 |
| Takemori, H | 1 |
| Kimura, S | 1 |
| Kudoh, I | 1 |
| Suzuki, H | 1 |
| Fukushi, M | 1 |
| Aisawa, T | 1 |
| Ishiguro, Y | 1 |
| Yoshiike, M | 1 |
| Osanai, S | 1 |
| Gérard, JP | 1 |
| Romestaing, P | 1 |
| Ardiet, JM | 1 |
| Sentenac, I | 1 |
| Mahé, M | 1 |
| Christie, DR | 1 |
| Bull, CA | 1 |
| Gebski, V | 1 |
| Langlands, AO | 1 |
| Rakovitch, E | 1 |
| Fyles, AW | 1 |
| Pintilie, M | 1 |
| Leung, PM | 1 |
| Kaneyasu, Y | 1 |
| Okawa, MK | 1 |
| Kokubo, N | 1 |
| Karasawa, K | 1 |
| Fukuhara, N | 1 |
| Toda, J | 1 |
| Okawa, T | 1 |
| Mori, T | 1 |
| Hongo, H | 1 |
| Kondo, K | 1 |
| Akamine, T | 1 |
| Hanada, N | 1 |
| Toyota, N | 1 |
| Yoshioka, M | 1 |
| Tabira, Y | 1 |
| Hiraoka, T | 1 |
| Kitamura, N | 1 |
| Lu, JD | 1 |
| Kim, RY | 2 |
| Lindner, H | 1 |
| Paulsen, T | 1 |
| Kaern, J | 1 |
| Tropé, C | 1 |
| Sause, W | 1 |
| Bundy, BN | 1 |
| Malfetano, JH | 1 |
| Hannigan, EV | 1 |
| Fowler, WC | 1 |
| Clarke-Pearson, DL | 1 |
| Liao, SY | 1 |
| Kono, T | 1 |
| Yamamoto, Y | 1 |
| Kakisaka, A | 1 |
| Tokusasi, Y | 1 |
| Miyokawa, N | 1 |
| Kasai, S | 1 |
| Dunst, J | 1 |
| Urba, SG | 1 |
| Orringer, MB | 1 |
| Turrisi, A | 1 |
| Iannettoni, M | 1 |
| Forastiere, A | 1 |
| Strawderman, M | 1 |
| Heydon, K | 1 |
| Eifel, P | 1 |
| Kresl, JJ | 1 |
| Schild, SE | 1 |
| Henning, GT | 1 |
| Donohue, J | 1 |
| Pitot, H | 1 |
| Nagorney, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142] | Phase 2 | 21 participants (Actual) | Interventional | 2020-07-15 | Active, not recruiting | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation[NCT01049100] | 250 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | |||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment[NCT00122772] | Phase 3 | 601 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters[NCT00603408] | Phase 2 | 5 participants (Actual) | Interventional | 2007-12-31 | Terminated (stopped due to Study was discontinued due to lack of accrual.) | ||
| Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA)[NCT03100409] | 137 participants (Actual) | Interventional | 2017-02-01 | Terminated (stopped due to The study was closed prematurely because the interim analysis found that subjects in the experimental group had less gastrointestinal toxicity.) | |||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)[NCT00815308] | Phase 2 | 55 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study[NCT05028231] | 46 participants (Anticipated) | Observational | 2021-06-05 | Recruiting | |||
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.[NCT03534713] | Phase 3 | 310 participants (Anticipated) | Interventional | 2020-07-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting. All detailed information regarding serious and other adverse events are listed in the Adverse Event module of these results. (NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 5 |
(NCT00603408)
Timeframe: 30 days post surgery (week 17-18)
| Intervention | participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 0 |
OS = Time from registration until death from any cause (NCT00603408)
Timeframe: Until study was terminated (23.5 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Cisplatin + Radiation + Recommended Surgery | 100 |
"Complete response: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level~Partial response: at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD~Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started,~Progressive disease: at least a 20% increase in the sum of the LD of the target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one more new lesions, or unequivocal progression of existing non-target lesions." (NCT00603408)
Timeframe: At the time of surgery (week 13)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Cisplatin + Radiation + Recommended Surgery | 2 | 3 | 0 | 0 |
DNA was extracted from tumor specimens.Screened for the presence of KRAS codon 12 and 13 mutations using a PCR clamping and melting curve technique. PCR amplification of the wild-type KRAS sequence was suppressed in this process by the incorporation in the reaction mix of a locked nucleic-acid oligomer16 spanning codons 12 and 13 of the KRAS gene. Post-PCR hybridization and melting curve analysis using fluorescently tagged oligonucleotides incorporated in the original PCR reaction permitted the identification and discrimination of distinct KRAS codon 12 and 13 missense mutations. (NCT00815308)
Timeframe: 07/29/2010-09/30/2010
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 53 |
The overall response rate was defined as the numbers of patients with a complete response (CR) or partial response (PR). CR was defined as no target lesion at follow-up computed tomography scan and barium swallow examination 3-6 weeks after completion of chemo-radiation. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT00815308)
Timeframe: 1 to 3 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 44 |
All patients were regularly monitored for possible adverse events, which were graded according to National Cancer Institute Common Toxicity Criteria version 3.0. (NCT00815308)
Timeframe: Every week during treatment and 1 month after therapy
| Intervention | participants (Number) |
|---|---|
| Cetuximab, Concurrent Chemo-radiotherapy | 55 |
4 reviews available for fluorouracil and Carcinoma, Adenosquamous
| Article | Year |
|---|---|
Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Adenosqu | 2015 |
Primary adenosquamous carcinoma of the liver: case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Fatal Out | 2002 |
[Cancer of the anal canal].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1990 |
Adenosquamous carcinoma of the rectum showing endocrine-cell differentiation: report of a case.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Fluorouraci | 1999 |
20 trials available for fluorouracil and Carcinoma, Adenosquamous
| Article | Year |
|---|---|
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2017 |
Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adeno | 2015 |
A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2009 |
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 8 | 2009 |
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Ca | 2010 |
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Adenosq | 2011 |
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2003 |
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2003 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach | 2004 |
Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2004 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adeno | 2007 |
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2007 |
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2008 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent cervical cancer with or without radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 1997 |
Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 1998 |
Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1999 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou | 2001 |
22 other studies available for fluorouracil and Carcinoma, Adenosquamous
| Article | Year |
|---|---|
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Fluor | 2023 |
Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carbopla | 2017 |
Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Car | 2014 |
Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Adenosquamous; Chemoradioth | 2015 |
Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carc | 2009 |
[Clinical analysis of 22 cases of esophageal adenosquamous carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Adenosquamou | 2009 |
Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Combined Moda | 2011 |
Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells.
Topics: Animals; Antigens, CD; Biomarkers, Tumor; Carcinogenicity Tests; Carcinoma, Adenosquamous; Drug Resi | 2012 |
Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2012 |
[A case of successful treatment by low-dose 5-fluorouracil and cisplatin for liver metastases of esophageal adenosquamous carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Dose-Response R | 2006 |
Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinom | 2007 |
Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; | 2007 |
Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Combined Modali | 2008 |
[Establishment and application of transplantable models of human esophageal carcinoma in nude mice].
Topics: Animals; Bleomycin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Disease Models, Animal; Esop | 1993 |
[A case of advanced esophageal cancer showing good partial response by combination therapy of low dose 5-FU and low dose CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Cisplatin; Drug Admi | 1996 |
Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 1995 |
Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplas | 1997 |
[Successful chemotherapy based on in vitro chemosensitivity testing in a case of recurrent thymic carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Adenosquamous; Cis | 1998 |
[How toxic and effective is simultaneous radiochemotherapy with hydroxyurea, 5-FU and cisplatin in cervix carcinoma?].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem | 1998 |
[Postoperative simultaneous radiochemotherapy improves survival in patients with cervical carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Aden | 2000 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Female; Fluorouraci | 2002 |